Background
==========

Newer genomic technologies like high-resolution microarrays and next generation exome sequencing have enabled the identification of many clinically relevant genetic variants for both Mendelian and complex disorders. Yet for many conditions the identified genes account for only a proportion of heritability. This observation coupled with the recognition of the functional relevance of non-genic regions \[[@B1]\] target these genomic segments as candidates for investigation for a role in disease.

ASD encompasses a range of neurodevelopmental disorders characterised by social impairment, communication difficulties and restricted, repetitive behavioural patterns. ASD, which is clinically and genetically heterogeneous, demonstrates high heritability, familial clustering and \~4:1 male to female bias. While there has been progress identifying risk genes, most are still unknown \[[@B2]\]. Analyses of rare (\<1% population frequency) CNVs, insertions and deletions (indels) and point mutations have most convincingly identified synaptic genes such as members of the Neuroligin (*NLGN3*, *NLGN4)*\[[@B3]\], Neurexin (*NRXN1*\[[@B4]\], *NRXN2*\[[@B5]\]*, NRXN3*\[[@B6]\]), SHANK (*SHANK1*\[[@B7]\], *SHANK2*\[[@B8]\], *SHANK3*\[[@B9]\]) families and Gephyrin \[[@B10]\] as highly-penetrant risk loci \[[@B2]\]. ASD subjects with multiple genetic risk factors for ASD and associated medical conditions are also known \[[@B11]\]. In addition, there are a few examples of mutations in ASD cases identified in non-genic segments of DNA \[[@B12]\] and non-coding RNAs \[[@B13]\]. Similar findings are even better documented in studies of intellectual disability \[[@B14],[@B15]\], which is observed in \~40% of cases of ASD. Focusing on the intergenic intervals of the genome, we performed a systematic genome-wide investigation to identify rare CNVs enriched in cases compared with controls \[[@B16]\] to identify known and novel ASD susceptibility loci.

Methods
=======

A collection of 1491 unrelated ASD cases were genotyped using either the Illumina 1M (993) or the Affymetrix SNP 6.0 platforms (498). The ASD subjects, all diagnosed using gold-standard instruments including Autism Diagnostic Interview and Autism Diagnostic Observation Schedule, are described elsewhere \[[@B16],[@B17]\]. Informed written consent was obtained from all participants, as approved by the Research Ethics Boards at The Hospital for Sick Children and McMaster University. For controls, 1287 samples from the SAGE cohort were genotyped on with the Illumina 1M and 1234 samples from the Ottawa Heart Institute (OHI) and 1123 from the POPGEN collections were genotyped on the Affymetrix SNP 6.0. CNV discovery was performed using previously described pipelines \[[@B16]-[@B18]\]. Three CNV detection tools were used for each platform (Birdsuite, iPattern and Genotyping Console for Affymetrix 6.0 and iPattern, QuantiSNP & PennCNV for Illumina 1 M). A subset of CNVs in both cases and controls were considered rare if they were present in \<1% of the overall dataset and these were further analysed if they failed to intersect or fall within a known gene (according to the NCBI Reference Sequence (RefSeq), August 2011). Rare genic CNVs identified from these data have been reported previously and from these data approximately 10% of cases carry a *de novo* or rare inherited CNV thought to contribute to ASD in that individual \[[@B16],[@B17],[@B19],[@B20]\]. All CNVs discussed were validated where DNA was available using independent laboratory methods such as long range or quantitative PCR and the mode of inheritance determined (Additional files [1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}).

Results and discussion
======================

Microarray data from a cohort of 1491 unrelated ASD probands were analysed for rare copy number variants as described previously \[[@B16],[@B17]\] and CNVs falling outside of known coding sequence were identified. A total of 212 non-coding genomic regions were determined as harboring overlapping CNVs in two or more unrelated ASD cases that were absent in control samples. Each region was examined for plausible biological function by comparison with multiple databases. Data was collated for evidence of expressed sequences from mRNA or EST data at GenBank or evolutionary conservation as well as functional predictions from the VISTA enhancer browser (<http://enhancer.lbl.gov/>) and Rfam (<http://rfam.sanger.ac.uk/>). The Database of Genomic Variants (<http://dgvbeta.tcag.ca/dgv/app/home>) was used to eliminate additional regions as non-ASD specific CNVs and regions with \>80% masked as repetitive sequences were removed. Loci were also prioritised as being of potential clinical significance in ASD due to proximity to genes considered known or candidate ASD risk genes \[[@B17]\].

Fifteen intergenic regions emerged as plausible candidate ASD risk loci and in all instances the defining CNV events were inherited. In one of these regions, an additional case (SK0167-003) was found with an overlapping CNV described by Marshall *et al.* (2008) \[[@B19]\] (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"} and Additional files [1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}). In 14 of 15, the intergenic interval identified has not been described before and in three regions the CNV neighboured a known ASD gene, namely, *CDH8* \[[@B21]\], *C3orf58* \[[@B22]\] and *NRXN1* \[[@B4]\]. In the case of the *NRXN1* gene, upstream CNVs found in five individuals impact the same mRNA (AK127244) reported elsewhere with a CNV in a family with ASD (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}A) \[[@B23]\]. Examples of other intergenic CNVs identified highlight regions at 8q24.12 upstream of *ZHX2*, 6p21.2 upstream of *MOCS1*, 11p12 upstream of *LRRC4C* (Figure [1](#F1){ref-type="fig"}B) and 7q21.11 upstream of *SEMA3C*, as putative novel ASD rearrangements. In one case (8-14208-3350), deletions were identified at three separate loci; 4q13.1 upstream of *EPHA5*, 11p14.3 upstream of *LUZP2* and 11p12 upstream of *LRRC4C* and another case (3-0496-003) carried a 46, XXY sex chromosome imbalance. Other CNVs found in these 41 cases are shown in Additional file [3](#S3){ref-type="supplementary-material"} and any or all of these may be contributing to the genetic load for ASD \[[@B11],[@B17]\]. Interestingly, all the CNVs identified through our analysis are inherited events. The significance of this observation is still to be determined but suggests incomplete and/or variable penetrance of phenotype, which is something often observed in ASD \[[@B6],[@B7],[@B17]\].

###### 

ASD specific CNVs in intergenic regions

  **Locus**      **Gene**                **Sample**     **CNV**     **Start**   **End**     **Size**   **Furthest distance from gene**   **Bin**
  -------------- ----------------------- -------------- ----------- ----------- ----------- ---------- --------------------------------- ---------
  2p16.3         *NRXN1* AK127244 mRNA   1-0045-004     loss        51405882    51524684    118802     1124                              ii
  8-3394-003     loss                    51439897       51479683    39786                                                                
  8-3394-003     loss                    51157414       51189362    31948                                                                
  8-14144-2420   loss                    51157414       51225851    68437                                                                
  1-0496-003     gain                    52220120       52238172    18052                                                                
  1-0449-003     loss                    52237072       52253660    16588                                                                
  3p22.3         *ARPP21*                2-1213-003     loss        34984049    35102773    118724     563                               ii
  3-0100-000     gain                    35086691       35094736    8045                                                                 
  3q24           *C3orf58 ZIC1, ZIC4*    1-0007-003     loss        146168760   146934953   766193     1383 1955, 1979                   i
  8-3093-004     loss                    146575437      146631141   55704                                                                
  4q13.1         *EPHA5*                 8-14208-3350   loss        66505324    66633530    128206     840                               i
  8-14186-3050   loss                    66515708       66633530    117822                                                               
  1-0138-004     loss                    66515708       66633530    117822                                                               
  2-0082-004     loss                    67045815       67134170    88355                                                                
  1-0455-003     loss                    67058506       67075558    17052                                                                
  6p21.2         *MOCS1*                 3-0139-000     gain        40021898    40078515    56617      168                               i or ii
  2-0139-003     gain                    40023327       40062155    38828                                                                
  1-0381-003     loss                    40174188       40209324    35136                                                                
  2-1368-003     loss                    40174188       40210694    36506                                                                
  7q21.11        *SEMA3C*                8-6258-03      loss        80431202    80512022    80820      96                                i
  1-0345-005     loss                    80482597       80517630    35033                                                                
  8p12           *UNC5D NRG1*            8-14243-3670   loss        34923482    34956067    32585      256 2183                          i
  3-0044-000     loss                    34923482       34956067    32585                                                                
  3-0300-000     loss                    34925149       34957854    32705                                                                
  8-14181-2940   loss                    34923482       34956067    32585                                                                
  8q24.13        *ZHX2*                  8-3317-003     gain        123572785   123625681   52896      237                               i or ii
  3-0186-000     loss                    123583028      123639417   56389                                                                
  9q33.1         *ASTN2*                 8-3055-004     loss        119254497   119374796   120299     98                                i
  3-0115-000     loss                    119314967      119319559   4592                                                                 
  9q34.2         *OLFM1 RXRA*            2-1272-003     gain        136479329   136604233   124904     508 8                             i
  2-1189-003     gain                    136480334      136598491   118157                                                               
  11p14.3        *LUZP2*                 8-14175-2820   loss        24177612    24316053    138441     160                               i or ii
  8-14059-1020   loss                    24262511       24303132    40621                                                                
  8-14208-3350   loss                    24262511       24303132    40621                                                                
  11p12          *LRRC4C*                8-14208-3350   gain        40304880    40703298    398418     196                               iii
  2-0272-003     loss                    40379668       40550356    170688                                                               
  SK0167-003     loss                    40417554       40610400    192846                                                               
  3-0208-000     loss                    40468058       40492541    24483                                                                
  11p12          *LRRC4C*                8-14032-600    loss        41990280    42021250    30970      1738                              i or ii
  8-3276-003     loss                    42243624       42279094    35470                                                                
  2-0286-003     loss                    42243624       42279094    35470                                                                
  11q13.2        *MRGPRD*                4-0023-003     loss        68486121    68493638    7517       10                                i
  2-1075-003     loss                    68486121       68500238    14117                                                                
  16q21          *CDH8*                  8-14251-3750   loss        61650435    61787984    137549     1030                              i or ii
                                         2-1175-003     loss        61658675    61755232    96557                                         

Location and size of all CNVs discovered are listed with the proposed associated candidate gene. Bin denotes possible mechanism of action by i) altering sequence elements required for regulating expression of neighboring genes ii) affecting undiscovered genes or non-coding RNAs iii) disrupting uncharacterised isoforms of adjacent genes. Genome browser views of all loci are shown in Figure [1](#F1){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}. All pedigrees are shown in Additional file [2](#S2){ref-type="supplementary-material"}. Additional sample SK0167-003 identified in reference \[[@B19]\].

![**Genome browser views of ASD specific CNVs at A) 2p16.3 B) 11p12 C) 8p12 and D) 4q13.1.** In each case, representative isoforms of known RefSeq genes, mRNA and/or Expressed Sequence Tags are shown. Deletions and duplications are represented by red and blue bars, respectively. In Figure 1A) a dashed line indicates a diploid region located between two adjacent deletions in the same individual. Additional browser views from other loci shown in Table [1](#T1){ref-type="table"} are included in Additional file [1](#S1){ref-type="supplementary-material"} A-J. In all cases where parental DNA was available, the CNVs shown were found to be inherited. Additional case SK0167-003 found in Marshall *et al.*\[[@B19]\].](1471-2164-14-499-1){#F1}

The mechanism of action of these rare CNVs in the pathogenesis of ASD could be (i) through altering the necessary copy number or positional context of key DNA sequence elements required for regulating the proper expression of nearby genes \[[@B1]\], (ii) affecting still undiscovered genes or non-coding RNAs residing in the CNV regions and (iii) disrupting uncharacterized isoforms of the adjacent annotated genes. In the first scenario, we find CNVs both upstream (e.g. *UNC5D* (Figure [1](#F1){ref-type="fig"}C), *MOCS1*, *ASTN2*, *SEMA3C*, *ZHX2*, *LUZP2*, *CDH8*) and down-stream (*C3orf58*, *RXRA*, *MRGPRD*) of known ASD risk genes and putative novel loci. For at least three regions (4q13.1, 6p21.2 and 11p12 (shown in Figure [1](#F1){ref-type="fig"}D, Additional file [1](#S1){ref-type="supplementary-material"}C and Figure [1](#F1){ref-type="fig"}B respectively)), our CNV mapping data in fact identify two distinct clusters of CNVs at the same locus, all overlapping spliced ESTs and thus with a possible regulatory role. Secondly, three independent CNV deletions interrupting a collection of spliced expressed sequenced tags approximately 330 kb proximal to *EPHA5* highlight a potentially newly discovered ASD risk gene (Figure [1](#F1){ref-type="fig"}D). Finally, longer isoforms of *LRRC4C* likely exist given the discovery of mRNAs DQ084201 and DQ084202. There are, of course, other functional DNA elements or modifications that need to be considered \[[@B24]\] as the mapping resolution increases.

Conclusions
===========

Given the challenges faced in interpreting the clinical significance of multitudes of genetic variants found in for example, whole genome sequencing \[[@B25]\], accruing evidence across multiple studies will advocate loci outside of known genes or other regulatory elements for further study, particularly for rare variants. In this light, these data provide a useful resource for comparison as new data sets of both CNVs and nucleotide-level variants become available to help fine-map additional discover new ASD risk loci. This general research strategy can also be applied to other disease gene studies.
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